|会社名||Anavex Life Sciences Corp （アナベックス・ライフ・サイエンシズ）|
|分野（sector）||Health Care ヘルスケア|
|産業（industry）||Biotechnology: Commercial Physical_Biological Resarch|
|業種||バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care）|
|概要||事業概要 アナヴェックス･ライフ・サイエンス(Anavex Life Sciences Corp.)は臨床段階のバイオ医薬品会社である。同社は神経変性疾患および神経発達疾患の治療用の差別化された治療薬の開発に従事する。その治療薬はアルツハイマー病（AD）、他の中枢神経系（CNS）疾患、疼痛および各種類の癌を治療するための薬物候補を含む。その研究開発パイプラインには、前臨床試験の各段階における臨床薬候補と多様な化合物が含まれる。製品パイプラインには、ANAVEX 2-73、ANAVEX 3-71、ANAVEX 1-41、ANAVEX 1037およびANAVEX 1066が含まれる。SIGMACEPTORディスカバリープラットフォームは、シグマ受容体の理解に基づいて、作用機序を有する小分子薬物候補を産生する。ANAVEX 1-41はシグマ-1アゴニストである。ANAVEX 1066は混合シグマ-1 /シグマ-2リガンドである。同社は事業から収入を得ていない。 アナベックス・ライフ・サイエンシズは米国の臨床段階のバイオ医薬品会社。アルツハイマ―病、中枢神経系疾患、前立腺がん、膵臓がんなどに焦点を当て、新しい候補薬の研究・開発を行う。シグマ受容体の働きに基づいて開発された、同社の「シグマセプタ―・ディスカバリ―・プラットフォ―ム」は、独特な方法により小分子候補薬を生産する。本社はニューヨーク。 Anavex Life Sciences Corp. is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, pain and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), recently completed a successful Phase 2a clinical trial for Alzheimer's disease. ANAVEX®2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 (blarcamesine) also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 (blarcamesine) for the treatment of Parkinson's disease. ANAVEX®3-71, which targets sigma-1 and muscarinic receptors, is a promising preclinical drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation.|
|本社所在地||51 West 52nd Street 7th Floor New York NY 10019 USA|
|代表者氏名||Christopher U. Missling クリストファー・ミッシング|
|代表者役職名||President Chief Executive Officer Secretary Director|
|市場名||NASDAQ Small Cap|
|決算概要||決算概要 BRIEF: For the nine months ended 30 June 2018 Anavex Life Sciences Corp revenues was not reported. Net loss increased 40% to $11.7M. Higher net loss reflects Research and development - Balancing val increase of 88% to $6.9M (expense) General and administrative - Balancing increase of 68% to $2.5M (expense) Stock-based Compensation in SGA increase of 95% to $2M (expense).|
Biofrontera, Synaptogenix top healthcare gainers; while Sio Gene, Anavex among losers 2022/02/01 15:02:51 Seeking Alpha
Biofrontera (BFRI) +14%. Synaptogenix (SNPX) +11%. Sio Gene Therapies (SIOX) -19%. Anavex Life Sciences (AVXL) -16%.
Anavex says late-stage trial for Rett syndrome met main goals 2022/02/01 12:37:27 Seeking Alpha
Announcing topline data from its AVATAR trial for ANAVEX2-73 (blarcamesine), Anavex Life Sciences (AVXL) said that the Phase 3 study met primary and secondary efficacy endpoints in
ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints for the Treatment of Adult Patients with Rett Syndrome 2022/02/01 12:00:00 Benzinga
Primary and all secondary efficacy and safety endpoints met, with consistent improvements in RSBQ AUC (p = 0.037), ADAMS (p = 0.010) and CGI-I (p = 0.037) response Efficacy endpoints demonstrated statistically significant and clinically meaningful reductions in Rett syndrome symptoms with related changes in potential biomarkers (GABA and L-AAA) of disease pathology Key milestone met to advance regulatory approval pathway for adult patients with Rett syndrome Company to host a webcast today at 8:30 a.m. ET NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL ), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer''s disease, Parkinson''s disease, Rett syndrome and other central nervous system (CNS) disorders, today reported positive top-line results from the Phase 3 randomized, double-blind, placebo-controlled AVATAR trial of ANAVEX ® 2-73 ( blarcamesine ) in adult female patients with Rett syndrome and demonstrated a statistically significant improvement over placebo for the primary efficacy endpoint as well as for all the secondary efficacy endpoints.
Integral Ad Science leads postmarket gainers; Apyx Medical top loser 2022/01/21 22:49:54 Seeking Alpha
Gainers: Integral Ad Science (IAS) +14%, Anavex Life Sciences (AVXL) +8%, Algoma Steel (ASTL) +5%, EMCORE (EMKR) +4%, CymaBay Therapeutics (CBAY) +4%.Losers: Apyx Medical (APYX)
Parkinson''s Disease Pipeline Offers Promising New Options for Treatment | DelveInsight 2022/01/18 01:00:00 Benzinga
Los Angeles, USA, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Parkinson''s Disease Pipeline Offers Promising New Options for Treatment | DelveInsight DelveInsight''s "Parkinson''s Disease Pipeline Insight" report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the Parkinson''s Disease pipeline landscapes. The report comprises Parkinson''s Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Parkinson''s Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Parkinson''s Disease pipeline products. Some of the key takeaways from the Parkinson''s Disease Pipeline Report Major Parkinson''s Disease companies such as Cerevel Therapeutics, Abbvie, Pharma Two B, Roche, Kissei Pharmaceutical, Peptron, Inc., Lundbeck A/S, AstraZeneca, Nobilis Therapeutics, Treefrog Therapeutics, Cantabio Pharmaceuticals, Anavex Life Sciences, Ipsen, Prevail Therapeutics, AFFiRiS, Sio Gene Therapies, UCB Pharma, Brain Neurotherapy Bio, Inc., Neuraly, Inc., NeuroDerm, BlueRock Therapeutics, Sun Pharma Advanced Research Company, Xoc Pharmaceuticals, Hong Kong WD Pharmaceutical, 1ST Biotherapeutics, Inc., Biogen, Denali Therapeutics, Inhibikase Therapeutics,Cerevance, Aspen Neuroscience,Prilenia Therapeutics,Cortexyme Inc.,Gain Therapeutics, Clexio Biosciences, Orpheris, Inc., Alkahest, Inc., and others are developing potential drug candidates to improve the Parkinson''s Disease treatment scenario.
Here''s Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday 2021/07/29 19:30:00 The Motley Fool
A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer''s disease is an extremely risky business.
Anavex Life''s Stock Declines Despite Data Shows Alzheimer''s Candidate Prevent Abeta-Induced Cognitive Decline In Animal Study 2021/07/29 14:08:22 Benzinga
Anavex Life Sciences Corp (NASDAQ: AVXL ) has reported new preclinical data for its Alzheimer''s candidate, ANAVEX2-73 (blarcamesine). Pre-treatment with blarcamesine repeated once daily for one week before the Aβ (Abeta) challenge was protective in the Aβ25-35 peptide … Full story available on Benzinga.com
Anavex Life Sciences rises on positive data for Alzheimers therapy in mouse study 2021/07/29 11:46:45 Seeking Alpha
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Significantly Prevented A (Abeta)-induced Cognitive Deficits with Confirmed Significant Biomarker-response in Animal Model of Alzheimers Disease 2021/07/29 11:00:00 Intrado Digital Media
Pre-Treatment with ANAVEX ® 2-73 entirely prevented Abeta-induced cognitive decline
Thinking about buying stock in Acorda Therapeutics, Ocular Therapeutix, Ocugen, Aerpio Pharmaceuticals, or Anavex Life Sciences? 2021/07/23 13:31:00 PR Newswire
NEW YORK, July 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACOR, OCUL, OCGN, ARPO, and AVXL. To see how InvestorsObserver''s proprietary scoring system rates these stocks, view the InvestorsObserver''s PriceWatch Alert by selecting the corresponding link.
Bronchial Spasms Market 2021-28 Notable Pace with H. Lundbeck A/S, Mallinckrodt, Anavex Life Sciences Corp, AstraZeneca, Boehringer Ingelheim, F. Hoffmann-La Roche, GlaxoSmithKline 2021/07/09 12:29:06 OpenPR
Bronchospasm also known as Bronchial Spasms is a sudden contraction of muscles in the walls of the bronchioles. It is caused by the release (degranulation) of substances from mast cells or basophils under the influence of anaphylatoxins. It causes difficulty
Global Glioblastoma Multiforme (GBM) Treatment Market Could Reach Nearly $1.8 Billion By 2027 2021/06/29 12:45:00 Benzinga
PALM BEACH, Fla., June 29, 2021 /PRNewswire/ -- Glioblastoma multiforme (GBM) is one of the areas where the research & development investments are high and where global studies are growing. Everyone is looking to solve the problem. GBM, a fast-growing and aggressive brain tumor, is a devastating brain cancer that can result in death in six months or less, if untreated; hence, it is imperative to seek expert neuro-oncological and neurosurgical care immediately, as this can impact overall survival. Brain and other nervous system cancer is the 10th leading cause of death for men and women. Globally, over 241,000 people die each year as a result of brain or nervous system cancer, with GBM being the most common form of the disease. According to iHealthcareAnaylist report , said that: "GBM has an incidence of two to three per 100,000 adults per year, and accounts for 52 percent of all primary brain tumors. Glioblastoma multiforme (GBM) is the most common and deadly brain tumor in adults. The incidence of GBM in the USA and Europe is 23 per 100,000.
Why This Anavex Life Sciences Analyst Is Lifting Their Price Target 2021/06/28 19:44:34 Benzinga
A Cantor Fitzgerald analyst is incrementally bullish on shares of Anavex Life Sciences, Corp (NASDAQ: AVXL ) after the release of Phase 2 data for the company''s lead candidate. The Anavex Analyst: Charles Duncan, Ph.D. maintained an Overweight rating on Anavex Life Sciences and raised the price target from $31 to $40. The Anavex Takeaways: Anavex released positive information Monday from Phase 2 clinical trials of its lead candidate drug ANAVEX 2-73 for treatment of Parkinsons disease dementia (PDD), establishing proof-of-concept and enhancing the likelihood of the usage of the drug for treatment in neurodegenerative diseases and developmental disorders, Duncan said. The Cantor analyst said his Full story available on Benzinga.com
Anavex Life Sciences Stock Rallies: Technical Levels To Watch 2021/06/28 18:44:03 Benzinga
Anavex Life Sciences Corp. (NASDAQ: AVXL ) shares traded higher Monday after the company announced ANAVEX2-73, the companys main pipeline drug, improved both primary cognitive and secondary MDS-UPDRS efficacy endpoints with significant biomarker correlation in placebo-controlled Phase 2 clinical trial for treatment of Parkinsons disease. Anavex Life Sciences was up 18.37% at $29.30 at last check. Anavex Life Sciences Daily Chart Analysis Shares have been trading in a sideways channel and tested resistance Monday. The stock is trading above both the 50-day moving average (green), and the 200-day moving Full story available on Benzinga.com
関連キーワード （バイオテクノロジ―_メディカルリサ―チ 米国株 アナベックス・ライフ・サイエンシズ AVXL Anavex Life Sciences Corp.）